Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 785.05

+2.4%

Feb 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (681)	9/10/2002 8:20:32 PM
From: Miljenko Zuanic	Read Replies (2) of 3560

WE, It is second very disappointing news (investor’s perspective, and those who are in desperate needs) for biologic anti-cancer drugs. Who knows what will future bring on this field? MBC isn't that bad indication for anti-VEGF therapy. Only very difficult one. The idea is going after metastatic sites (at primary tumor and distant spread) early before they growth into new tumor. However, for this indication Xeloda (oral 5-FU) is not used alone. It is combined with another chemo agent, like Taxotere to increase killing effect and prolong survival. Message 16328789 So, first problem (my speculation) for Avista is that Xeloda alone was not sufficiently efficacious to give Avista chance to do what it is suppose to do. Second we do not know what are progression and death factors? Progression of the primary BCs or metastatic development and progress (nudes, bones, lung, liver,...), or both. Another issue is Avista doses and pts status prior enrollment? (Avista isn't without side effects, so the healthier they are the higher doses they may tolerate) REGN VEGF-T is searching for activity in different indications. It suppose to be better tolerated and with superior activity (active toward VEGFx isoform and some activity toward PlGF2). One thing is sure REGN does have deep knowledge about angiogenesis mechanisms and tumor growth. A is very complex and any single approach may not work well. Something will be learned from these failures. Only the problems may be that each pharma may not share full data with rest of the scientific community. And that is sad too. My motto is that in science there are no negative results. It is part of the learning curve. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next